ArticleBreast cancer research and treatment2026
Self-reported racial and ethnic discrimination in patient-provider interactions and the initiation of adjuvant therapies for breast cancer in the pathways study.
Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDespite advancements in breast cancer adjuvant therapies, some patients with indications may not receive treatment. We examined the association of self-reported racial/ethnic discrimination in patient-provider interactions and the receipt of clinically indicated therapies.
methodsThe Pathways Study is a prospective cohort of women diagnosed with invasive breast cancer from 2005 to 2013 at Kaiser Permanente Northern California. Racial/ethnic discrimination in patient-provider interactions was assessed from the Interpersonal Processes of Care survey at baseline, 6 months, and 24 months post-diagnosis. Logistic regression compared women who did not initiate clinically-indicated adjuvant therapy with those who did overall, and by race and ethnicity. Covariates included race and ethnicity, age at diagnosis, country of birth, education level, income, marital status, and American Joint Committee on Cancer staging.
resultsOverall, 3,610 women had indication for hormonal therapy, 2,450 for chemotherapy, and 3,258 for radiation therapy. In multivariable analyses, women reporting discrimination were at increased odds of not initiating hormonal therapy (adjusted odds ratio [aOR] = 1.43, 95% CI = 1.05-1.93) than those who did not self-report discrimination, regardless of their race/ethnicity. An increased odds of non-initiation for reported discrimination was found for radiation therapy (aOR = 1.26, 95% CI = 0.99-1.61), although it was not statistically significant. There was no association for chemotherapy initiation (aOR = 0.96, 95% CI = 0.69-1.33).
conclusionSelf-reported racial/ethnic discrimination in patient-provider interactions was associated with the non-initiation of hormonal therapy in women with breast cancer. Further studies are needed to explore the impact of this association on breast cancer prognosis. CLINICAL
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.